Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Viracta Therapeutics Inc VIRX

Healthcare Biotechnology
Viracta Therapeutics, Inc. is a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers, which impact patients worldwide. The Company’s lead product candidate is an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir (collectively, Nana-val). Nana-val is being evaluated... see more

Recent & Breaking News (NDAQ:VIRX)

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights

GlobeNewswire March 6, 2014

Sunesis to Present at Upcoming Investor Conferences

GlobeNewswire February 28, 2014

Sunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights

GlobeNewswire February 28, 2014

Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants

GlobeNewswire February 27, 2014

Sunesis Announces Proposed Public Offering of Common Stock and Warrants

GlobeNewswire February 26, 2014

Catalysts Drive These Stocks: Mara Goldstein

Equities.com February 21, 2014

Most Active Stocks Range from New Bitcoin Store to Chinese Media Company: Bitcoin Shop, Inc. (OTCQB: TUCND), Well Power, Inc. (OTCQB: VOELD), Sunesis Pharmaceuticals Inc. (NASDAQ: SNSS, Sohu.com Inc. (NASDAQ: SOHU)

Accesswire February 11, 2014

Five Star Equities Issues New Research Reports on ADEP, CYTK, SMT and SNSS

Accesswire February 10, 2014

Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data

GlobeNewswire February 10, 2014

Sunesis to Present at Upcoming Investor Conferences

Globe Newswire February 6, 2014

Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs

Globe Newswire January 9, 2014

Sunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Evaluating Vosaroxin in Combination With Azacitidine in MDS

Globe Newswire December 10, 2013

Sunesis Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference

Globe Newswire November 27, 2013

Sunesis Pharmaceuticals Reports Third Quarter Financial Results and Recent Highlights

Globe Newswire November 12, 2013

Sunesis Pharmaceuticals Announces Initiation of Phase 2 Cohort of MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS

Globe Newswire October 30, 2013

Sunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase I/II Trial Evaluating Vosaroxin in Myelodysplastic Syndrome

Globe Newswire October 28, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on BCRX, INCY, LXRX and SNSS

Accesswire September 27, 2013

Sunesis Pharmaceuticals Completes Enrollment in Phase 3 VALOR Trial of Vosaroxin in AML

Globe Newswire September 25, 2013

Sunesis to Present at BioCentury's 2013 Newsmakers in the Biotech Industry Conference

Globe Newswire September 19, 2013

Sunesis to Present at the 2013 Stifel Nicolaus Healthcare Conference

Globe Newswire September 4, 2013